Who are Omass's investors?

Omass's investors include GV (Google Ventures), Oxford Science Enterprises, Sanofi Ventures, Syncona, Northpond Ventures.

Where is Omass headquartered?

Omass is headquartered in Oxford, GB.

Omass

Oxford, GB · Founded 2016 · 75 employees on LinkedIn · 5 known investors

Find your way into Omass

Paths you didn't know you had: your email and LinkedIn already hold routes to the Omass team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

OMass is a biotech company that originated as a spinout from Oxford University, developing specialized treatments for patient populations with high unmet medical needs. The company builds integrated development and commercialization capabilities while partnering to advance programs addressing large indications.

Biotech Deep Tech Digital Health Healthtech Medical Devices

Founders & leadership

Omass was founded in 2016 by Professor Dame Carol Robinson, Idlir Liko, Jonathan Hopper, and Hsin Yung (Jason) Yen.

Professor Dame Carol RobinsonFounder and Chair of Scientific Advisory Board

Idlir LikoFounder

Jonathan HopperVice President, Platforms and Founder

Hsin Yung (Jason) YenFounder

Ros Deegan CEORos Deegan has 20 years of biotech and pharmaceutical industry experience, including business development roles at Bicycle Therapeutics, Trevena, and GSK. She holds an MBA from INSEAD and a first-class degree from Cambridge University.

Investors · 5

GV (Google Ventures)✓ confirmed by OmassMountain View · $250K – $50M

How we know: GV (Google Ventures)'s portfolio page · the company's own site · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

Oxford Science Enterprises✓ confirmed by OmassOxford · $63.5K – $31.8M

How we know: Oxford Science Enterprises's portfolio page · the company's own site · Not right? Tell us

Sanofi Ventures✓ confirmed by OmassCambridge · $5M

How we know: Sanofi Ventures's portfolio page · the company's own site · a partner's Signal profile · the VCSheet dataset · Not right? Tell us

Syncona✓ confirmed by OmassLondon

How we know: Syncona's portfolio page · the company's own site · open dataset · 5k.vc investor directory · Not right? Tell us

Northpond Ventures✓ confirmed by OmassBethesda · $100K – $5M

How we know: the company's own site · a partner's Signal profile · Not right? Tell us

Frequently asked questions

What does Omass do?: OMass is a biotech company that originated as a spinout from Oxford University, developing specialized treatments for patient populations with high unmet medical needs. The company builds integrated development and commercialization capabilities while partnering to advance programs addressing large indications.
Who founded Omass?: Omass was founded by Professor Dame Carol Robinson, Idlir Liko, Jonathan Hopper, Hsin Yung (Jason) Yen in 2016.
Who are Omass's investors?: Omass's investors include GV (Google Ventures), Oxford Science Enterprises, Sanofi Ventures, Syncona, Northpond Ventures.
Where is Omass headquartered?: Omass is headquartered in Oxford, GB.